Download PDF
Thromb Haemost 1987; 57(01): 011-016
DOI: 10.1055/s-0038-1651052
Original Articles
Schattauer GmbH Stuttgart

Indices of Fibrinogen Proteolysis and Platelet Activation During the Resolution of Pulmonary Embolism

I Yudelman
The Veterans Administration Medical Center and SUNY Health Science Center at Brooklyn, Brooklyn, NY, USA
› Author Affiliations
Further Information

Publication History

Received 18 March 1986

Accepted after revision 30 September 1986

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Indices of fibrinogen cleavage by thrombin (fibrinopeptide A, FPA); by plasmin (BB1-42 and serum FDP); of the platelet release reaction (betathromboglobulin and platelet factor 4); and antithrombin III (AT III) levels were measured serially in 46 patients with pulmonary emboli in whom either substantial (SR) or impaired (IR) resolution was documented. The mean FPA level in the 25 patients with IR was significantly higher than the level in the 21 patients with SR (p <0.01). The increased thrombin activity in the IR group was not due to AT III deficiency or increased platelet reactivity but the elevated FPA levels in the presence of therapeutic levels of anticoagulation indicated that the dose of heparin was inadequate. The higher BB1-42 and FDP levels in this group reflected the increased plasmin activity that follows increased thrombin activity. In a multivariate discriminant analysis, only the FPA data could be used to predict the degree of resolution.

Increased thrombin action impairs resolution presumably by producing greater amounts of accreted fibrin on the impacted embolus.

Keywords

Fibrinogen proteolysis in pulmonary embolism
 

  • References

  • 1 Dalen JE, Mathur VS, Evans H, Haynes FW, Pur-Shahrieri A, Stein P, Dexter L. Pulmonary angiography in experimental pulmonary embolism. Am Heart J 1966; 72: 509-520
    CrossrefPubMedGoogle Scholar
  • 2 Tow D, Wagner Jr HN. Recovery of pulmonary arterial blood flow in patients with pulmonary embolism. N Engl J Med 1967; 276: 1053-1059
    CrossrefPubMedGoogle Scholar
  • 3 Moser KM, Guissan M, Bartimmo EE. In vivo and post morten dissolution rates of pulmonary emboli and venous thrombi in the dog. Circulation 1973; 48: 170-178
    CrossrefPubMedGoogle Scholar
  • 4 Urokinase Pulmonary Embolism Trial. Circulation 1973; 47 Suppl (02) 1-108
    CrossrefPubMedGoogle Scholar
  • 5 Wilson III JE, Frenkel EP, Pierce AK, Johnson RL, Winga ER, Curry GL, Mierzwiak DS. Spontaneous fibrinolysis in pulmonary embolism. J Clin Invest 1971; 50: 474-480
    CrossrefPubMedGoogle Scholar
  • 6 Thomas DP, Gurewich V, Ashford TP. Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolisms. N Engl J Med 1966; 274: 953-956
    CrossrefPubMedGoogle Scholar
  • 7 Cade J, Hirsh J, Regoeczi E. Mechanisms for elevated Fibrin/Fibrinogen Degradation Products in Acute Experimental Pulmonary Embolism. Blood 1972; 45: 563-568
    PubMedGoogle Scholar
  • 8 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner G, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
    CrossrefPubMedGoogle Scholar
  • 9 Nossel HL, Wasser J, Kaplan KL, La Gamma KS, Yudelman I, Canfield RE. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. J Clin Invest 1979; 64: 1371-1378
    CrossrefPubMedGoogle Scholar
  • 10 Kaplan KL, Nossel HL, Drillings M, Lesznik G. Radioimmnoassay platelet factor 4 and B-thromboglobulin. Development and application to studies of platelet release in relation to fibrinopeptide A generation. Brit J Haematol 1978; 39: 129-144
    CrossrefPubMedGoogle Scholar
  • 11 Owen J, Kvam D, Nossel HL, Kaplan KL, Kernoff PBA. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood 1982; 61: 476-482
    PubMedGoogle Scholar
  • 12 Lane D, Ireland H, Wolff S, Grant R, Jennings S, Allen-Mersh T. Plasma concentrations of Fibrinopeptide A, Fibrinogen fragment Bbl-42 and B-thromboglobulin following total hip replacement. Thromb Res 1982; 26: 111-115
    CrossrefPubMedGoogle Scholar
  • 13 Cronlund M, Hardin J, Burton L, Lee L, Haber E, Bloch KJ. Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus. J Clin Invest 1976; 58: 142-151
    CrossrefPubMedGoogle Scholar
  • 14 Peuscher FW, Cleton FJ, Armstrong L, Stoepman-van Dalen EA, Van Mourik JA, Van Aken WG. Significance of plasma fibrinopeptide A (FPA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14
    PubMedGoogle Scholar
  • 15 Kaplan KL. Betathromboglobulin. In: Progress in Hemostasis and Thrombosis. Spaet TH. (ed). Vol. 5 pp. 153-178 Grune and Stratton; New York: 1980
    Google Scholar
  • 16 Yudelman I, Greenberg J. Factors affecting Fibrinopeptide A levels in patients with venous thromboembolism during anticoagulant therapy. Blood 1982; 59: 787-792
    PubMedGoogle Scholar
  • 17 Urokinase Pulmonary Embolism Trial. Circulation 1973; 47 Suppl (02) 49
    PubMedGoogle Scholar
  • 18 Kockum C. Radioimmunoassay of Fibrinopeptide A - Clinical Applications. Thromb Res 1976; 8: 225-236
    CrossrefPubMedGoogle Scholar
  • 19 Odegard OR. Evaluation of an amidolytic heparin cofactor assay method. Thromb Res 1975; 7: 351-360
    CrossrefPubMedGoogle Scholar
  • 20 Merskey C, Lalezari D, Johnson AJ. A rapid simple sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med 1969; 131: 871-876
    CrossrefPubMedGoogle Scholar
  • 21 Kaplan KL, Owen J. Radioimmunoassay of Platelet factor 4 and Betathromboglobulin. In: Methods in Enzymology. Colowick SP, Kaplan NO. (eds). pp 83-101 Academic Press; New York: 1982
    Google Scholar
  • 22 Robert GD, Steele P, Torrie JH. Principles and Procedures of Statistics. McGraw Hill; New York: 1960. chapter 15, pp 305-331
    Google Scholar
  • 23 Mardia KV, Kent JP, Bibby JM. Multivariate Analysis. Academic Press; New York: 1979. chapter 11: pp 300-332
    Google Scholar
  • 24 Marciniak E, Farley CH, DeSimone PA. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-231
    PubMedGoogle Scholar
  • 25 Marciniak E, Gockerman J. Heparin induced decrease in circulating antithrombin III. Lancet 1977; 11: 581-583
    PubMedGoogle Scholar
  • 26 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of Protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
    CrossrefPubMedGoogle Scholar
  • 27 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528
    CrossrefPubMedGoogle Scholar
  • 28 deBoer AC, Han P, Turpie A GG, Butt R, Zielinsky A, Genton E. Plasma and urine beta thromboglobulin concentrations in patients with deep vein thrombosis. Blood 1981; 58: 693-698
    PubMedGoogle Scholar
  • 29 Niewiarowski S, Rucinski B, James P, Lindahl U. Platelet antiheparin proteins and antithrombin III interact with different binding sites on the heparin molecule. FEBS Lett 1979; 102: 75-82
    CrossrefPubMedGoogle Scholar
  • 30 Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76
    CrossrefPubMedGoogle Scholar
  • 31 Kaplan KL, Owen J. Plasma levels of B-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-201
    PubMedGoogle Scholar
  • 32 Nossel HL. Relative proteolysis of the fibrinogen Bb chain by the thrombin and plasmin as a determinant of thrombosis. Nature 1981; 291: 165-166
    CrossrefPubMedGoogle Scholar
  • 33 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe M. Specificity of a monoclonal antibody for the NH2 terminal region of fibrin. Molecular Immunology 1984; 21: 89-94
    CrossrefPubMedGoogle Scholar